U.S. pharma large copyright scrapped two experimental weight loss pills final calendar year—a after-each day tablet, lotiglipron, on account of elevated liver enzymes and a twice-everyday pill, danuglipron, as a result of strong Unwanted side effects—but CEO Albert Bourla has claimed the company is decided to “Enjoy and acquire” within the